RxDoctor Payments Data

R Baum, MD

Cardiovascular Disease · San Antonio, TXNPI 1013994987

Payments from drug & device makers

$3,722in general payments, 2019–2025

Across 172 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$825
  • Boston Scientific$703
  • Pfizer$328
  • Medtronic$224
  • Amarin Pharma, Inc.$213
  • Johnson & Johnson$209
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,722100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,722 in reported general payments places this provider in the 50th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$256,340
Medicare patients
1,276
Services billed
3,759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban278$357,394
XareltoRivaroxaban210$259,299
FarxigaDapagliflozin Propanediol151$191,409
EntrestoSacubitril/Valsartan65$101,040
JardianceEmpagliflozin84$99,267
Repatha SureclickEvolocumab54$58,956
VascepaIcosapent Ethyl31$24,850
Metoprolol Succinate802$11,712
Repatha SyringeEvolocumab11$8,737
Icosapent Ethyl30$8,624
Atorvastatin Calcium876$8,102
Rosuvastatin Calcium747$7,996
Ezetimibe223$6,194
Valsartan207$6,118
Eplerenone41$3,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$328$357,394278 claims
Johnson & JohnsonXarelto$209$259,299210 claims
AstraZenecaFarxiga$50$191,409151 claims
NovartisEntresto$825$101,04065 claims
Boehringer IngelheimJardiance$49$99,26784 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →